The national i-Lab competition has just unveiled its 2025 prize list, with a major accolade for the healthcare ecosystem in the South of France: seven innovative companies from the Eurobiomed community are among the winners, and one of them, Dolinnov, has even been awarded a coveted i-Lab grand prize.
A true label of DeepTech excellence, i-Lab is one of France 2030's flagship initiatives to support the emergence of innovative technology companies. With grants of up to 600,000 euros, this prestigious competition, which has already honored over 3,800 projects since 1999, enables winners to take crucial steps in R&D, prototyping and intellectual property.
Diversity of award-winning healthcare innovations
The award-winning innovations testify to the excellence and diversity of healthcare solutions developed in our region. The i-Lab 2025 competition honored Dimicare's new generation of precision antibiotics, Spima Therapeutics' immunotherapies, Lymphodys' innovative treatment for secondary lymphedema, Neocor Therapeutics' gene therapies for cardiac regeneration, DeepPulseNeuro's minimally invasive monitoring tool for epilepsy, and Massalia Therapeutics' innovative therapies for fibrosis and tumors.
Grand Prix for Dolinnov
A special mention goes to Dolinnov, which was awarded one of the 9 i-Lab Grand Prizes by the jury. A fine reward for this Montpellier-based biotech, which is developing a solution for chronic neuropathic and inflammatory pain.
Eurobiomed's know-how, combining in-house expertise on i-Lab applications, the cross-sectional views of the Strategic Project Council and in-depth knowledge of France 2030 schemes, played a key role in the success of several of these projects. " Eurobiomed's support provided us with valuable feedback from experts familiar with i-Lab applications. For me, this was a decisive factor in obtaining funding", stresses Juan Garcia, CEO of DimiCare.
L’équipe Eurobiomed se tient d’ores et déjà prête à accompagner les pépites de l’édition 2026, si ce concours d’innovation vous intéresse venez-nous en parler !
